社會公益: 資助中國貧困的小朋友
- 2022-09-27 07:33:24
2000年Qualtech在臺北成立,其後在世界各地成立了多個據點,多年来Qualtech 除了始終堅持提供醫療器材的法規諮詢、產品註冊、臨床設計與執行、當地授權代理人、上市後追蹤等高品質與專業的服務之外,也不忘記屬於Qualtech的企業責任,正因為我們從事著與醫療相關的產業,我們更加著重於幫助與關愛弱勢團體。
了解更多2000年Qualtech在臺北成立,其後在世界各地成立了多個據點,多年来Qualtech 除了始終堅持提供醫療器材的法規諮詢、產品註冊、臨床設計與執行、當地授權代理人、上市後追蹤等高品質與專業的服務之外,也不忘記屬於Qualtech的企業責任,正因為我們從事著與醫療相關的產業,我們更加著重於幫助與關愛弱勢團體。
了解更多Qualtech's big topic for this month's edition provides an overview of the Unique Device Identification (UDI) system implemented by territories serviced by Qualtech for medical devices. The UDI system aims to improve patient safety, traceability, and identification of medical devices on the market. The implementation of the UDI system offers benefits such as faster traceability, standardized post-market safety activities, and improved buying and waste disposal policies.
了解更多The Therapeutic Goods Administration (TGA) created a plan to help Australian medical device sponsors and stakeholders transition to the new EU Medical Device Regulation (MDR). The EU then extended the transition period, so the TGA reviewed its original plan. An updated strategy guideline has been published by the TGA regarding the transition and reclassification of certain medical devices.
了解更多Correction action of medical devices is included in the eRPS. The structure of the online submission dossier of corrective action is provided.
了解更多Center for medical device evaluation (CMDE) revised "Guidance for Registration of Intense Pulsed Light Equipment" and "Guidance for Registration of Ophthalmic Optical Instrument".
了解更多This document aims to ensure that the summary of the clinical investigation report presents information about the design, conduct, analysis, and results of the clinical investigation in terms and in a format that are easily understandable to the intended user of the medical device.
了解更多This guidance aims to provide a clear understanding of what changes to design or intended purpose would be considered 'significant'. It also provides several flowcharts in order to facilitate a harmonized judgement of the significance of a change.
了解更多HSA would like to consult the industry/stakeholders regarding updates and revisions of GN-14 Guidance on the Risk Classification of In Vitro Diagnostic Medical Devices (R3). The key update includes clarification notes on the classification of control materials and software, also clarifications to the risk classification rules 1-5. The consultation period is open from 2-30 May 2023 through email to HSA.
了解更多The Food and Drug Administration (FDA) has recently released guidance aimed at streamlining the premarket notification (510(k)) submissions for peripheral percutaneous transluminal angioplasty (PTA) and specialty catheters. This guidance provides manufacturers and FDA staff with comprehensive recommendations to ensure regulatory compliance and enhance the safety and effectiveness of these medical devices
了解更多The Circular 10/2023/TT-BYT was issued on May 11, 2023, amending some templates of the Circular 19/2021/TT-BYT, which was combined with the Decree 98/2021/ND-CP.
了解更多我們透過Cookies蒐集您的瀏覽記錄,以了解您如何使用我們的網站,從而分析及改善您的體驗。如繼續使用我們的網站,即表示您接受我們使用 Cookies。